HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Andrzej Kazarnowicz Selected Research

Neutropenia

2/2016TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Andrzej Kazarnowicz Research Topics

Disease

3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
02/2016 - 03/2015
3Disease Progression
07/2015 - 09/2014
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
11/2019 - 09/2014
2Exanthema (Rash)
07/2015 - 03/2015
1Injection Site Reaction
02/2016
1Fatigue
02/2016
1Neutropenia
02/2016
1Vaccinia
02/2016
1Acne Vulgaris
07/2015
1Sleepiness
09/2014

Drug/Important Bio-Agent (IBA)

2Etoposide (VP 16)FDA LinkGeneric
11/2019 - 09/2014
2necitumumabIBA
07/2015 - 03/2015
2Cisplatin (Platino)FDA LinkGeneric
07/2015 - 03/2015
1PlatinumIBA
11/2019
1durvalumabIBA
11/2019
1AntigensIBA
02/2016
1Interleukin-2 (IL2)IBA
02/2016
1TG4010IBA
02/2016
1AntibodiesIBA
07/2015
1GemcitabineFDA Link
07/2015
1Pemetrexed (MTA)FDA Link
03/2015
1Carboplatin (JM8)FDA LinkGeneric
09/2014
1obatoclaxIBA
09/2014

Therapy/Procedure

4Drug Therapy (Chemotherapy)
02/2016 - 09/2014
2Therapeutics
07/2015 - 03/2015
1Immunotherapy
02/2016